Post embolization syndrome in doxorubicin eluting chemoembolization with DC bead

Το τεκμήριο παρέχεται από τον φορέα :
Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών   

Αποθετήριο :
Πέργαμος   

δείτε την πρωτότυπη σελίδα τεκμηρίου
στον ιστότοπο του αποθετηρίου του φορέα για περισσότερες πληροφορίες και για να δείτε όλα τα ψηφιακά αρχεία του τεκμηρίου*



Post embolization syndrome in doxorubicin eluting chemoembolization with DC bead

Pomoni, M. Malagari, K. Moschouris, H. Spyridopoulos, T.N. Dourakis, S. Kornezos, J. Kelekis, A. Thanos, L. Chatziioanou, A. Hatjimarkou, I. Marinis, A. Koskinas, J. Kelekis, D.

scientific_publication_article
Επιστημονική δημοσίευση - Άρθρο Περιοδικού (EL)
Scientific publication - Journal Article (EN)

2012


Background/Aims: The investigation of Post Embolization Syndrome (PES) in patients with Hepatocellular Carcinoma (HCC) after treatment with doxorubicin loaded DC Bead (DEB-DOX). Methodology: The study included 237 patients treated with sequential DEB-TACE performed at set time intervals every two months until 3 sessions/6 month f-u. Patients were ECOG 0-1, Child-Stage-A (n=116, 48.9%) and B (n=121, 51%). Embolizations were as selective as possible with DC Bead of 100-300μm in diameter followed by 300-500μm loaded with doxorubicin at 37.5mg/mL of hydrated bead (max:150mg). Results: PES regardless of severity was observed in up to 86.5%. However grade 2 PES ranged between 25% and 42.19% across treatments. Temperatures above 38°C were seen in 22.7% to 38.3% across treatments. No statistically significant increase of PES was seen in beads of 100-300μm in diameter; incidence of fever and pain presented correlation with the extent of embolization (p=0.0001-0.006 across treatments). Baseline tumor diameter was associated with incidence of fever (p=0.0001-0.001). Duration of fever correlated with the extent of embolization p=0.008). PES was not associated with elevation of liver enzymes and was correlated with degree of necrosis (p<0.001). Conclusions: PES after DEB-DOX represents tumor response to treatment and does not represent collateral healthy liver damage. © H.G.E. Update Medical Publishing S.A. (EN)

Αγγλική γλώσσα

Ερευνητικό υλικό ΕΚΠΑ

https://creativecommons.org/licenses/by-nc/4.0/




*Η εύρυθμη και αδιάλειπτη λειτουργία των διαδικτυακών διευθύνσεων των συλλογών (ψηφιακό αρχείο, καρτέλα τεκμηρίου στο αποθετήριο) είναι αποκλειστική ευθύνη των αντίστοιχων Φορέων περιεχομένου.